HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Nov. 4, 2020 (HealthDay News) -- Some patients with COVID-19 have long-lasting dermatologic manifestations, according to a study presented at the annual congress of the European Academy of Dermatology and Venereology, held virtually from Oct. 29 to 31.
Devon E. McMahon, from Massachusetts General Hospital in Boston, and colleagues examined the duration of dermatologic symptoms of COVID-19 and evaluated the presence of persistent "long-hauler" skin symptoms, defined as dermatologic symptoms of COVID-19 that persisted ≥60 days. Overall, 990 total cases and 303 laboratory-confirmed or suspected COVID-19 cases with dermatologic manifestations were included.
Information on dermatologic symptom duration was available for 224 total cases and 90 laboratory-confirmed cases. The researchers found that the median symptom duration was 12 days for all symptoms and seven days for patients with laboratory-confirmed disease. For patients with laboratory-confirmed COVID-19, morbilliform and urticarial eruptions lasted a median of seven and four days, respectively, with a maximum duration of 28 days. In laboratory-confirmed cases, papulosquamous eruptions lasted 20 days, with one confirmed long-hauler eruption lasting 70 days. In patients with suspected COVID-19 and in laboratory-confirmed cases, pernio/chilblains lasted a median of 15 and 10 days, respectively; six patients with pernio/chilblains had toe symptoms lasting ≥60 days. Two patients continued to experience pernio for more than 130 days.
"Our findings reveal a previously unreported subset of patients with long-standing skin symptoms from COVID-19, in particular those with COVID toes," a coauthor said in a statement. "This data adds to our knowledge about the long-term effects of COVID-19 in different organ systems."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022